Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Catalent
Company Monitoring Page for Catalent
latest headlines for company on cafepharma
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy
BioSpace
Fri, 04/5/24 - 11:52 am
Tags:
Novo Nordisk
,
M&A
,
Catalent
,
SEC
Novo Nordisk and Catalent deal: net positive or negative for industry?
Biopharma Reporter
Tue, 02/20/24 - 11:06 am
Tags:
Novo Nordisk
,
Catalent
,
M&A
,
Wegovy
,
Ozempic
3 questions hanging over the Novo-Catalent deal
Pharma Voice
Wed, 02/14/24 - 10:55 am
Tags:
Novo Nordisk
,
Catalent
,
drug manufacturing
,
Ozempic Wegovy
,
Eli Lilly
As Catalent prepares to join Novo family, CDMO's sales continue to slide
Fierce Pharma
Fri, 02/9/24 - 11:21 am
Tags:
Catalent
,
CDMOs
,
earnings
,
Novo Nordisk
FDA finds control lapses at Catalent plant being sold to Novo
Reuters
Tue, 02/6/24 - 11:36 pm
Tags:
FDA
,
drug manufacturing
,
regulatory
,
Novo Nordisk
,
Catalent
Novo Holdings acquires Catalent in $16.5B deal, aiming to boost Wegovy production as demand soars
Medical Marketing and Media
Mon, 02/5/24 - 11:06 pm
Tags:
Novo Nordisk
,
Catalent
,
drug manufacturing
,
Wegovy
,
M&A
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
CNBC
Mon, 02/5/24 - 10:10 am
Tags:
Novo Nordisk
,
Catalent
,
drug manufacturing
,
M&A
,
Wegovy
,
Ozempic
Catalent delays quarterly filing with SEC on $700 mln impairment charge
Reuters
Tue, 11/14/23 - 11:18 am
Tags:
Catalent
,
SEC
,
M&A
Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott
Investopedia
Wed, 08/30/23 - 10:03 am
Tags:
Catalent
,
Wegovy
,
Novo Nordisk
,
Elliott Management
Catalent facing board shake-up pressure from activist investor Elliott
Fierce Pharma
Fri, 07/21/23 - 10:06 am
Tags:
Catalent
,
investors
,
activist investors
,
CDMO
Catalent Delays Earnings Call, Shaves $400M Off FY23 Guidance
BioSpace
Tue, 05/9/23 - 10:37 am
Tags:
Catalent
,
earnings
,
CDMOs
Danaher backs away from Catalent as CDMO struggles with productivity problems: report
Fierce Pharma
Tue, 04/18/23 - 10:15 am
Tags:
Catalent
,
Danaher
,
M&A
,
CDMOs
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Investors Business Daily
Tue, 02/7/23 - 11:14 am
Tags:
Catalent
,
Danaher
,
Thermo Fisher Scientific
,
M&A
Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal
Endpoints
Thu, 01/5/23 - 04:58 pm
Tags:
Sarepta Therapeutics
,
SRP-9001
,
gene therapy
,
Duchenne Muscular Dystrophy
,
CDMOs
,
Catalent
Catalent to build a new $40M analytical services facility in North Carolina's Research Triangle
Endpoints
Wed, 12/14/22 - 07:25 pm
Tags:
Catalent
,
North Carolina
,
RTP
,
analytical services
,
R&D
Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent
BioSpace
Thu, 11/3/22 - 07:34 pm
Tags:
Exelixis
,
Catalent
,
antibody-drug conjugate
Catalent buys partially built biologics plant with plans to shell out $160M to finish it
Fierce Pharma
Thu, 04/7/22 - 10:32 am
Tags:
CDMOs
,
Catalent
,
biologics
,
drug manufacturing
Catalent completes $30m expansion to biologics network
Biopharma Reporter
Tue, 03/22/22 - 10:03 am
Tags:
Catalent
,
drug manufacturing
,
biologics
Novo Nordisk's Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analysts
Fierce Pharma
Thu, 01/27/22 - 10:47 am
Tags:
Novo Nordisk
,
Catalent
,
Wegovy
,
obesity
,
FDA
Inside the Catalent FDA citation said to trigger Novo Nordisk's Wegovy supply hiccup
Fierce Pharma
Tue, 01/18/22 - 10:49 am
Tags:
Catalent
,
FDA
,
Novo Nordisk
,
Wegovy
,
supply chain
Pages
1
2
3
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
a dog would most likely chase a: cat, rock, house
*
Fill in the blank.